Are Nice And The SMC Diverging In Their Assessment Of Oncology Drugs?

October 4, 2018 Danielle Twigg

Educational poster presented at ISPOR Meeting, Barcelona, November 2018

Previous Article
A Budget Impact Analysis Of Cladribine Tablets Versus Alternative High Efficacy Treatments For Relapsing Multiple Sclerosis (RMS) In The UK
A Budget Impact Analysis Of Cladribine Tablets Versus Alternative High Efficacy Treatments For Relapsing Multiple Sclerosis (RMS) In The UK

Next Article
Pan-European HTA – Where We Have Been, Where We Are Going?
Pan-European HTA – Where We Have Been, Where We Are Going?